Amporin Pharmaceuticals receives the CHF 150,000 Kick to develop a breakthrough class of small-molecule drugs
25.07.2024
Amporin Pharmaceuticals received a CHF 150,000 investment from Venture Kick to develop amyloid pore inhibitors to treat deadly degenerative diseases.
 Amporin Co-Founders
|
 |
Over 50 deadly degenerative diseases—including Alzheimer’s, Parkinson’s, type II diabetes, and many rare neurodegenerative disorders—are linked to protein misfolding and aggregation. These diseases collectively affect over half a billion people and kill 3.6 million people annually, costing society USD 3 trillion per year. Yet no effective treatments exist to halt or reverse the progressive degeneration that ultimately leads to death.
Amporin Pharmaceuticals aims to develop a new class of small-molecule drugs that block and eliminate toxic soluble oligomers and pores from within cell membranes. These toxic substances accumulate and kill cells by puncturing holes in cell membranes, causing loss of homeostasis and progressive degeneration. The company plans to develop and license the first effective acute oral disease-modifying treatments for up to six major diseases—including Alzheimer's disease and type II diabetes—with an initial focus on Parkinson's and ALS (amyotrophic lateral sclerosis).
Parkinson’s disease alone affects around 1 million people in the US and 10 million people globally. The current global drug market for Parkinson's disease is about USD 6 billion per year, with a potential market of USD 15 billion per year for the first effective disease-modifying treatments.
The CHF 150,000 from Venture Kick will allow the company to establish its core operations and build a complete in vitro data package to validate and demonstrate the unique advantages of its technology to potential investors and licensing partners.
Amporin’s founding team includes CEO Dr. Kelvin Stott, CSO Dr. Hervé Schaffhauser, and CMO Prof. Daniel Umbricht, each with over 20 years of CNS drug development and R&D leadership experience in multiple Big Pharma companies, as well as biotech startups.
“Venture Kick has been a critical source of support in helping us to build a world-class company around a world-changing technology,” highlighted Kelvin Stott, Amporin Pharmaceuticals’ Co-Founder and CEO. “Without it, we had no way forward to turn our potential into reality.”
Amporin Co-Founders: CSO Dr. Hervé Schaffhauser, CEO Dr. Kelvin Stott, and CMO Prof. Daniel Umbricht
Amporin Pharmaceuticals aims to develop a new class of small-molecule drugs that block and eliminate toxic soluble oligomers and pores from within cell membranes. These toxic substances accumulate and kill cells by puncturing holes in cell membranes, causing loss of homeostasis and progressive degeneration. The company plans to develop and license the first effective acute oral disease-modifying treatments for up to six major diseases—including Alzheimer's disease and type II diabetes—with an initial focus on Parkinson's and ALS (amyotrophic lateral sclerosis).
Parkinson’s disease alone affects around 1 million people in the US and 10 million people globally. The current global drug market for Parkinson's disease is about USD 6 billion per year, with a potential market of USD 15 billion per year for the first effective disease-modifying treatments.
The CHF 150,000 from Venture Kick will allow the company to establish its core operations and build a complete in vitro data package to validate and demonstrate the unique advantages of its technology to potential investors and licensing partners.
Amporin’s founding team includes CEO Dr. Kelvin Stott, CSO Dr. Hervé Schaffhauser, and CMO Prof. Daniel Umbricht, each with over 20 years of CNS drug development and R&D leadership experience in multiple Big Pharma companies, as well as biotech startups.
“Venture Kick has been a critical source of support in helping us to build a world-class company around a world-changing technology,” highlighted Kelvin Stott, Amporin Pharmaceuticals’ Co-Founder and CEO. “Without it, we had no way forward to turn our potential into reality.”
Amporin Co-Founders: CSO Dr. Hervé Schaffhauser, CEO Dr. Kelvin Stott, and CMO Prof. Daniel Umbricht